CBUS

SEC source: 0001127602-18-023816 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F1 · security: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-023816 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,648

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-023108 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,668

Underlying: Common Stock · 4,083 shares

Expires 2024-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-023108 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $17.75 to $18.16, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-023108 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021822 · form4.xml · nonDerivative · entry 1

Godard Alain · CIK 0001712102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,320

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.60 to $21.425, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · balance_after: Includes 33,320 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 5,880 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021750 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 226,336

Underlying: Common Stock · 4,666 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-021750 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $20.395 to $20.765, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021750 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,648

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021748 · form4.xml · derivative · entry 3

Arbadji Michel · CIK 0001712089 · Director of Business Developme

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Common Stock · 6,500 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-021748 · form4.xml · nonDerivative · entry 2

Arbadji Michel · CIK 0001712089 · Director of Business Developme

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,990

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017.

F1 · balance_after: Includes 24,990 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 4,410 will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021748 · form4.xml · nonDerivative · entry 1

Arbadji Michel · CIK 0001712089 · Director of Business Developme

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,490

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 24,990 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 4,410 will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021363 · form4.xml · nonDerivative · entry 1

Sahoo Manoj · CIK 0001712226 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,634

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2017.

F2 · balance_after: Includes 68,600 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017, remain unvested and will vest quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021023 · form4.xml · nonDerivative · entry 1

Cellectis S.A. · CIK 0001627281 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,713,175

F1 · shares: These shares were purchased pursuant to Share Purchase Agreements, dated June 13, 2018, from individuals with Restricted Stock Units of Calyxt, Inc. vesting on June 14, 2018 at the closing price of the shares on The Nasdaq Global Market on June 14, 2018. The reporting person undertakes to provide the staff of the SEC, upon request, full information regarding the number of shares purchased from each individual.

SEC source: 0001127602-18-021074 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F1 · shares: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person.

F2 · balance_after: Includes 85,443 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021072 · form4.xml · nonDerivative · entry 1

Tripodi Federico A. · CIK 0001712282 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,300

F1 · shares: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person.

F2 · balance_after: Includes 166,600 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 29,400 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021070 · form4.xml · nonDerivative · entry 1

Sahoo Manoj · CIK 0001712226 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,124

F1 · shares: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person.

F2 · balance_after: Includes 68,600 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017, remain unvested and will vest quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021068 · form4.xml · nonDerivative · entry 1

Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,600

F1 · shares: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person.

F2 · balance_after: Includes 16,660 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 2,940 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021066 · form4.xml · nonDerivative · entry 1

Dumont Philippe · CIK 0001712186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,294

F1 · shares: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person.

F2 · balance_after: Includes 16,660 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 2,940 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021064 · form4.xml · nonDerivative · entry 1

Bowers Glenn R · CIK 0001712179 · Vice President of Breeding

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,617

F1 · shares: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person.

F2 · balance_after: Includes 6,664 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 784 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 45 months.

SEC source: 0001127602-18-021028 · form4.xml · nonDerivative · entry 1

Choulika Andre · CIK 0001712190 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,448

F1 · shares: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person.

F2 · balance_after: Includes 133,280 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 23,520 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021146 · form4.xml · nonDerivative · entry 1

Corkal Bryan W.J. · CIK 0001712240 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,307

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.

F2 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $18.65-$19.25, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · balance_after: Includes 68,600 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017, remain unvested and will vest quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-021141 · form4.xml · nonDerivative · entry 1

Arbadji Michel · CIK 0001712089 · Director of Business Developme

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,990

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017.

F2 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $18.65-$18.97, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · balance_after: Includes 24,990 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 4,410 will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-018535 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 231,002

Underlying: Common Stock · 4,666 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-018535 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,521

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50-$16.76, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-018535 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,187

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0000899243-18-013568 · doc4.xml · nonDerivative · entry 1

Cellectis S.A. · CIK 0001627281 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,650,000

F1 · kind: Purchased directly from Calyxt, Inc. in Calyxt, Inc.'s public offering pursuant to the registration statements on Form S-1 (333-224945 and 333-225017). The shares of common stock were purchased at the public offering price.

SEC source: 0001127602-18-017122 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,751

Underlying: Common Stock · 4,083 shares

Expires 2024-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-017122 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,521

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $15.12-$16.15, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-017122 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-015184 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,668

Underlying: Common Stock · 4,666 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-015184 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,521

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $16.7001-$16.92, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-015184 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,187

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-014419 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,834

Underlying: Common Stock · 4,083 shares

Expires 2024-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-014419 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,521

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $14.04-$14.97, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-014419 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-012594 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,334

Underlying: Common Stock · 4,666 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-012594 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F2 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50-$18.35, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001127602-18-012594 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,666

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-18-011458 · form4.xml · derivative · entry 9

Godard Alain · CIK 0001712102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,300

Underlying: Common Stock · 10,000 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-18-011458 · form4.xml · nonDerivative · entry 6

Godard Alain · CIK 0001712102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,200

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.

SEC source: 0001127602-18-011458 · form4.xml · nonDerivative · entry 5

Godard Alain · CIK 0001712102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-18-011458 · form4.xml · derivative · entry 8

Godard Alain · CIK 0001712102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,300

Underlying: Common Stock · 10,000 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-18-011458 · form4.xml · nonDerivative · entry 4

Godard Alain · CIK 0001712102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,200

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.

SEC source: 0001127602-18-011458 · form4.xml · nonDerivative · entry 3

Godard Alain · CIK 0001712102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-18-011290 · form4.xml · derivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,917

Underlying: Common Stock · 4,083 shares

Expires 2024-12-03

F3 · price: The price reported in Column 8 is weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69-$18.50, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

F2 · derivative.underlying_shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

SEC source: 0001127602-18-011460 · form4a.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,917

Underlying: Common Stock · 4,083 shares

Expires 2024-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-011460 · form4a.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F2 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69-$18.50, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001127602-18-011460 · form4a.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,083

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-18-011458 · form4.xml · derivative · entry 7

Godard Alain · CIK 0001712102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,300

Underlying: Common Stock · 10,000 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.